A better way to treat cancer, Brian Druker
Interviewee: Brian Druker. Brian Druker talks bout a better way to treat cancer.
But it always seemed to me that you were using very harsh chemicals to cure a disease and that was fantastic but it still seemed there had to be a better way and the better way was to understand what was driving the growth of these cancer cells and if we could get to that point maybe we could treat this disease more rationally. And I always figured wouldn't it be great just to be a part of that discovery that was likely to occur over the next 20 or 30 years.
cancer cells,harsh chemicals,cancer drug,gleevec,brian druker,discovery
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
Brian Druker talks about how Gleevec has restored patients' hope for the future.
Brian Druker talks about sense of urgency.
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Brian Druker talks about Bud, the first patient restored to health by Gleevecâ¢.
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.